Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Aug 23:2:6.
doi: 10.1186/1472-6904-2-6.

Appetite suppressants and valvular heart disease - a systematic review

Yoon K Loke  1 , Sheena Derry, Angharad Pritchard-Copley
Affiliations

Appetite suppressants and valvular heart disease - a systematic review

Yoon K Loke et al. BMC Clin Pharmacol. .

Abstract

Background: Although appetite suppressants have been implicated in the development of valvular heart disease, the exact level of risk is still uncertain. Initial studies suggested that as many as 1 in 3 exposed patients were affected, but subsequent research has yielded substantially different figures. Our objective was to systematically assess the risk of valvular heart disease with appetite suppressants.

Methods: We accepted studies involving obese patients treated with any of the following appetite suppressants: fenfluramine, dexfenfluramine, and phentermine. Three types of studies were reviewed: controlled and uncontrolled observational studies, and randomized controlled trials. Outcomes of interest were echocardiographically detectable aortic regurgitation of mild or greater severity, or mitral regurgitation of moderate or greater severity.

Results: Of the 1279 patients evaluated in seven uncontrolled cohort studies, 236 (18%) and 60 (5%) were found to have aortic and mitral regurgitation, respectively. Pooled data from six controlled cohort studies yielded, for aortic regurgitation, a relative risk ratio of 2.32 (95% confidence intervals 1.79 to 3.01, p < 0.00001) and an attributable rate of 4.9%, and for mitral regurgitation, a relative risk ratio of 1.55 (95% confidence intervals 1.06 to 2.25, p = 0.02) with an attributable rate of 1.0%. Only one case of valvular heart disease was detected in 57 randomized controlled trials, but this was judged unrelated to drug therapy.

Conclusions: The risk of valvular heart disease is significantly increased by the appetite suppressants reviewed here. Nevertheless, when considering all the evidence, valvulopathy is much less common than suggested by the initial, less methodologically rigorous studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative risks for FDA AR with appetite suppressants.
Figure 2
Figure 2
Relative risks for FDA AR with appetite suppressants after exclusion of Khan's study.
Figure 3
Figure 3
Relative risks for FDA MR with appetite suppressants.
See this image and copyright information in PMC

References

    1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–588. doi: 10.1056/NEJM199708283370901. - DOI - PubMed
    1. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep. 1997;46:1061–1066. - PubMed
    1. Schiller NB. Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't. J Am Coll Cardiol. 1999;34:1159–1162. doi: 10.1016/S0735-1097(99)00315-0. - DOI - PubMed
    1. Burger AJ, Charlamb MJ, Singh S, Notarianni M, Blackburn GL, Sherman HB. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Int J Cardiol. 2001;79:159–165. doi: 10.1016/S0167-5273(01)00412-0. - DOI - PubMed
    1. Fisher EA, Ruden R. Pulmonary artery pressures and valvular lesions in patients taking diet suppressants. Cardiovasc Rev Rep. 1998;19:13–16.

Publication types

MeSH terms